… look forward to collaborating with ProQR and its exciting RNA editing technologies.” About ProQR ProQR Therapeutics is … Nucleotides”, or EONs, recruit an endogenously expressed RNA editing system called ADAR, which it can direct to change …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
… scientific advisory board Dr. Yu’s research focuses on RNA editing and his expertise will help to develop the Company’s novel RNA editing technologies Presented at the European Cystic …
… will focus exclusively on the development of its Axiomer RNA editing technology platform across multiple therapeutic … In November, the Company plans to present its proprietary RNA base-editing Axiomer technology at the Oligonucleotide …
… development and further advance our novel Axiomer ® RNA editing platform. With these events we look forward to … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change …